Predictive Oncology INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Axe Compute Inc. announced a significant five-year, $1.5 billion contract to deploy a dedicated AI infrastructure cluster in the U.S., boosting its 2026 signed contract value to over $3 billion.
Axe Compute Inc. announced it has secured over $1.3 billion in new customer contracts for its AI infrastructure build program, exceeding its annual goal.
Axe Compute Inc. has filed an 8-K to update its risk factors, reflecting a strategic shift toward a capital-intensive, owned-asset GPU infrastructure model.
Axe Compute Inc. has filed a prospectus supplement to increase its at-the-market (ATM) equity offering capacity to $100 million.
Axe Compute Inc. will host a conference call on May 18, 2026, to discuss its first quarter 2026 financial results.
Axe Compute Inc. announced a significant 36-month contract valued at approximately $260 million for a dedicated cluster of 2,304 NVIDIA B300 GPUs and AI storage.
Axe Compute Inc. has announced the resignation of CFO Josh Blacher and the appointment of Jeremy Yaukey-Witter as his successor.
Axe Compute Inc. announced the appointment of Kyle Okamoto as President and reported approximately $12 million in new executed agreements, projecting $835,000 in monthly income for Q2 2026.
Axe Compute Inc. announces the termination of its former CEO and the appointment of Christopher Miglino, signaling a strategic pivot towards decentralized AI compute and digital infrastructure.
Axe Compute Inc. announced the resignations of two directors and its Chief Investment Officer, effective in January 2026.
Axe Compute Inc., formerly Predictive Oncology, announced a strategic pivot into high-performance AI infrastructure and an increase in CEO Raymond F. Vennare's compensation.
Predictive Oncology Inc. announced a corporate name change to Axe Compute Inc. and a new NASDAQ ticker symbol, AGPU, effective December 11, 2025.
Predictive Oncology Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement, ensuring its continued listing on the Nasdaq Capital Market.
Predictive Oncology Inc. stockholders approved an increase in the equity incentive plan shares, auditor ratification, and warrant share issuance at their 2025 annual meeting.
Predictive Oncology Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following the completion of two private investment in public equity transactions.
Predictive Oncology Inc. details its new digital asset treasury strategy focused on the Aethir ecosystem to capitalize on the booming AI infrastructure market.
Predictive Oncology reported significant Q3 2025 losses driven by a derivative liability from its new digital asset strategy focused on Aethir's ATH token.
Predictive Oncology Inc. filed a prospectus supplement to increase the maximum aggregate offering price of common stock it can sell through its at-the-market program to $18.33 million.
Predictive Oncology Inc. announced the date and record date for its 2025 annual meeting of stockholders, along with the deadline for shareholder proposals.
Predictive Oncology Inc. closed two private placements totaling $343.5 million to fund a new digital asset treasury strategy focused on Aethir's ATH token.
Predictive Oncology Inc. is undergoing a significant strategic shift, raising $200 million in a private placement to establish a digital asset treasury focused on Aethir tokens (ATH) and appointing new leadership.
Predictive Oncology Inc. announced two private placements totaling $344.4 million to fund a new digital asset treasury strategy focused on Aethir (ATH) tokens, alongside its existing AI drug discovery business.
Predictive Oncology Inc. has implemented a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective September 29, 2025.
Predictive Oncology Inc. awarded restricted stock units to its CEO and Interim CFO, vesting October 31, 2025, under its 2024 Equity Incentive Plan.
Predictive Oncology Inc. announced a private placement of 543,544 common shares to an accredited investor, raising approximately $413,093 for working capital.
Predictive Oncology reported a reduced net loss and cash burn in Q2 2025, alongside a significant revenue decline, as it prepares for a major ChemoFx market expansion and secures new funding.
Predictive Oncology Inc. has received an extension from Nasdaq until December 8, 2025, to regain compliance with listing requirements, including minimum stockholders' equity and bid price.
Predictive Oncology Inc. has retrospectively revised its 2024 financial statements to reflect the divestment of its Eagan business as discontinued operations, while pursuing a merger with Renovaro Inc. and focusing on its core AI-driven oncology drug discovery.
Predictive Oncology Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, triggering a 180-day period to regain compliance.
Predictive Oncology Inc. has entered into a Standby Equity Purchase Agreement with YA II PN, LTD., providing the company access to up to $10 million in equity financing for general corporate purposes.